Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

Pharmacogenomics

Volumn 11, Issue 9, 2010, Pages 1223-1234

  Elens, Laure ^a   Vandercam, Bernard ^b   Yombi, Jean Cyr ^b   Lison, Dominique ^a   Wallemacq, Pierre ^a,b   Haufroid, Vincent ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

ABCB1; antiretroviral drug; CYP2A6; CYP2B6; CYP3A5; efavirenz; HIV; pharmacogenetics; SNP; UGT2B7

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; DIDANOSINE; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 2B7; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 1; TENOFOVIR; ZIDOVUDINE;

ADULT; ALLELE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PATIENT COMPLIANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77957145661     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.94     Document Type: Article

References (46)

1. Csajka C, Marzolini C, Fattinger K et al.: Population pharmacokinetics and effects of efavirenz in patients with human immunodefciency virus infection. Clin. Pharmacol. Ther. 73(1), 20-30 (2003).
2. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1), 71-75 (2001).
3. Stahle L, Moberg L, Svensson JO, Sonnerborg A: Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical effects. Ther. Drug. Monit. 26(3), 267-270 (2004).
4. Clifford DB, Evans S, Yang Y et al.: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann. Intern. Med. 143(10), 714-721 (2005).
5. Rotger M, Colombo S, Furrer H et al.: Infuence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005).
6. Colombo S, Telenti A, Buclin T et al.: Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther. Drug. Monit. 28(3), 332-338 (2006).
7. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C: Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37(9), 1793-1796 (2009).
8. Desta Z, Saussele T, Ward B et al.: Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(8), 547-558 (2007).
9. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH: CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23(16), 2101-2106 (2009).
10. Kwara A, Lartey M, Sagoe K W, Rzek NL, Court MH: CYP2B6 (c.516G-T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67(4), 427-436 (2009).
11. Leger P, Dillingham R, Beauharnais CA et al.: CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J. Infect. Dis. 200(6), 955-964 (2009).
12. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003).
13. Haberl M, Anwald B, Klein K et al.: Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics 15(9), 609-624 (2005).
14. Innocenti F, Liu W, Fackenthal D et al.: Single nucleotide polymorphism discovery and functional assessment of variation in the UDP- glucuronosyltransferase 2B7 gene. Pharmacogenet. Genomics 18(8), 683-697 (2008).
15. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
16. Wojnowski L, Kamdem LK: Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol. 2(2), 171-182 (2006).
17. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M: Polymorphic CYP2B6: molecular mechanisms and emerging clinical signifcance. Pharmacogenomics 8(7), 743-759 (2007).
18. Haas DW, Ribaudo HJ, Kim RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS Clinical Trials Group study. AIDS 18(18), 2391-2400 (2004).
19. Haas DW, Gebretsadik T, Mayo G et al.: Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 199(6), 872-880 (2009).
20. Motsinger AA, Ritchie MD, Shafer RW et al.: Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 16(11), 837-845 (2006).
21. Rotger M, Tegude H, Colombo S et al.: Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81(4), 557-566 (2007).
22. Brumme ZL, Dong W W, Chan KJ et al.: Infuence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17(2), 201-208 (2003).
23. Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359(9300), 30-36 (2002).
24. Haas DW, Wu H, Li H et al.: MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J. Acquir. Immune Defc. Syndr. 34(3), 295-298 (2003).
25. Haas DW, Smeaton LM, Shafer RW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfnavir: an adult aids Clinical Trials Group Study. J. Infect. Dis. 192(11), 1931-1942 (2005).
26. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75(1), 13-33 (2004).
27. Nasi M, Borghi V, Pinti M et al.: MDR1 C3435T genetic polymorphism does not infuence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17(11), 1696-1698 (2003).
28. Saitoh A, Singh KK, Powell CA et al.: An MDR1-3435 variant is associated with higher plasma nelfnavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19(4), 371-380 (2005).
29. Tsuchiya K, Gatanaga H, Tachikawa N et al.: Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319(4), 1322-1326 (2004).
30. Winzer R, Langmann P, Zilly M et al.: No infuence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8(12), 531-534 (2003).
31. Mukonzo JK, Roshammar D, Waako P et al.: A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68(5), 690-699 (2009).
32. Hogeland GW, Swindells S, McNabb JC et al.: Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 81(1), 69-75 (2007).
33. Elens L, Veriter S, Di Fazzio, V et al.: Quantifcation of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clin. Chem. 55(1), 170-174 (2009).
34. Elens L, Veriter S, Yombi JC et al.: Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(20-21), 1805-1814 (2009).
35. Furman PA, Fyfe JA, St Clair MH et al.: Phosphorylation of 3́-azido-3́-deoxythymidine and selective interaction of the 5́-triphosphate with human immunodefciency virus reverse transcriptase. Proc. Natl Acad. Sci. USA 83(21), 8333-8337 (1986).
36. Cabrera SE, Santos D, Valverde MP et al.: Infuence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodefciency virus patients. Antimicrob. Agents Chemother. 53(7), 2791-2798 (2009).
37. Furukawa M, Nishimura M, Ogino D et al.: Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. 95(6), 520-529 (2004).
38. Wang H, Jin G, Wang H et al.: Genetic susceptibility of lung cancer associated with common variants in the 3́ untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer 115(3), 595-607 (2009).
39. Blevins-Primeau AS, Sun D, Chen G et al.: Functional signifcance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 69(5), 1892-1900 (2009).
40. Hulgan T, Donahue JP, Hawkins C et al.: Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J. Acquir. Immune Defc. Syndr. 34(2), 119-126 (2003).
41. + natural killer cells. Pharmacogenetics 11(4), 293-298 (2001).
42. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
43. Hasse B, Gunthard HF, Bleiber G, Krause M: Efavirenz intoxication due to slow hepatic metabolism. Clin. Infect. Dis. 40(3), E22-E23 (2005).
44. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V: Infuence of 516G T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40(9), 1358-1361 (2005).
45. Gatanaga H, Hayashida T, Tsuchiya K et al.: Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45(9), 1230-1237 (2007).
46. Dauchy S, Dutheil F, Weaver RJ et al.: ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107(6), 1518-1528 (2008).